Business
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer,
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nVir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada.\n\nA live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.\n\nAbout Vir Biotechnology\n\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250512919764/en/\n\nMedia\nCorporate Communications, Vir Biotechnology\[email protected]\n\nInvestors\nRichard Lepke\nSenior Director, Investor Relations\[email protected]\n\nSource: Vir Biotechnology, Inc.","length":3473,"tagName":"div"}]